PERSPECTIVE: Betting on a Malaria Vaccine
3rd Nov 2005, 20:01 GMT
Sometime within the next two years, clinical researchers are expected to begin inoculating at least 2000 African infants in the largest trial ever undertaken of an experimental vaccine for malaria. ...
PERSPECTIVE: Betting on a Malaria Vaccine related news:
- GSK malaria vaccine boosted by Gates grant — Pharmaceutical Business Review Online
- Bethesda nonprofit lands $108M grant for malaria work — Latest news from Washington Business Journal
- Gates Foundation awards $108M to local group for malaria work — bizjournals.com Health Care:Pharmaceuticals headlines
- PanAfrica: Project Moves Closer to Malaria Vaccine for Children — AllAfrica News: Health and Medicine
- Bill Gates pledges US$258 million to fight malaria — Bink.nu
- Bill Gates Pledges $258 Million to Fight Malaria — ABC News: Health
- Hilton Humanitarian Prize Goes to 'Partners In Health' — VOA News: Human Interest
- Gates’ $258M Grant for Malaria — Red Herring
- WHO malaria figures are 'flawed' — BBC News | Programmes | File on 4 | UK Edition
- 'Little progress' in malaria war — BBC News | In Depth | 2004 | world trade | UK Edition
Latest news from New England Journal of Medicine -- Recent Issues:
- EARLY RELEASE: Reducing the Door-to-Balloon Time for Myocardial Infarction with ST-Segment Elevation
- EARLY RELEASE: Strategies for Reducing the Door-to-Balloon Time in Acute Myocardial Infarction
- EARLY RELEASE: Myocardial Infarction and the Open-Artery Hypothesis
- EARLY RELEASE: Coronary Intervention for Persistent Occlusion after Myocardial Infarction
- PERSPECTIVE: Recalibrating Medicare Payments for Inpatient Care
- PERSPECTIVE: Violence and Mental Illness -- How Strong is the Link?
- PERSPECTIVE: Murder or Mercy? Hurricane Katrina and the Need for Disaster Training
- ORIGINAL ARTICLE: Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
- ORIGINAL ARTICLE: Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
- ORIGINAL ARTICLE: Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia